title: [A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin].
abstract: There has been an increase in the number of patients treated with pegylated interferon (PEG-IFN) and ribavirin due to the better antiviral efficacy. The main serious adverse events of PEG-IFN plus ribavirin combination therapy are bone marrow suppression and hemolytic anemia. However, there are few reports of vasculitis occurring during PEG-IFN therapy. We describe a patient who developed vasculitis during the treatment of chronic hepatitis C with PEG-IFN and ribavirin.
authors: Department of Internal Medicine, Korea University Medical College, Guro Hospital, Seoul, Korea.
authors: Youn Ho
authors: YH
authors: Kim
authors: Woo Sik
authors: WS
authors: Han
authors: Sun Jae
authors: SJ
authors: Lee
authors: Sung Nam
authors: SN
authors: Oh
authors: Do Won
authors: DW
authors: Choi
authors: Kwan Soo
authors: KS
authors: Byun
authors: Jong Eun
authors: JE
authors: Yeon
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008111:Liver Function Tests; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects; D014657:Vasculitis / Q000139:chemically induced*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a